Blue Owl Capital Holdings’s Context Therapeutics CNTX Stock Holding History

Blue Owl Capital Holdings’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.63M	Sell	2,934,015 -2,155,000	-42%	-$4.37M	0.24%	34
2026 Q1	$13.3M	Sell	5,089,015 -2,343,891	-32%	-$5.47M	3.58%	9
2025 Q4	$10.9M	Buy	7,432,906 +25,000	+0.3%	+$29.2K	3.37%	8
2025 Q3	$7.18M	Hold	7,407,906	–	–	2.23%	15
2025 Q2	$4.85M	Buy	7,407,906 +40,000	+0.5%	+$28.8K	1.57%	18
2025 Q1	$4.51M	Buy	7,367,906 +1,009,978	+16%	+$879K	1.45%	18
2024 Q4	$6.68M	Buy	6,357,928 +946,638	+17%	+$1.64M	1.54%	17
2024 Q3	$10.6M	Buy	5,411,290 +250,000	+5%	+$555K	2.05%	14
2024 Q2	$10.3M	Buy	+5,161,290	New	+$8.9M	2.88%	12

Other funds holding CNTX

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Blue Owl Capital Holdings's CNTX Position: Q2 2026 in Review

Blue Owl Capital Holdings reduced its Context Therapeutics (CNTX) stake by 42% in Q2 2026, selling an estimated $4.37M and leaving 2,934,015 shares worth $1.63M. The position accounts for 0.24% of the portfolio, ranked #34.

Blue Owl Capital Holdings first reported a position in CNTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $13.3M in Q1 2026. 43 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

Blue Owl Capital Holdings held 2,934,015 shares of Context Therapeutics worth $1.63M as of Q2 2026.
Blue Owl Capital Holdings sold 2,155,000 Context Therapeutics shares in Q2 2026, an estimated $4.37M.
Context Therapeutics made up 0.24% of Blue Owl Capital Holdings's portfolio in Q2 2026, its #34 holding.
Blue Owl Capital Holdings first reported a position in Context Therapeutics in Q2 2024 and has held it in 9 quarters since.
Blue Owl Capital Holdings's Context Therapeutics position peaked at $13.3M in Q1 2026.
43 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.